Customized nanotechnology based treatment of Oral Cancer

基于纳米技术的口腔癌定制治疗

• 批准号: 8713626
• 负责人: KuanJu Chen
• 金额: $ 22.07万
• 依托单位: PRIVO TECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8713626
• 关键词: Address; Adverse effects; American Cancer Society; Animals; Applications Grants; Architecture; Area; Back; Biological Availability; Biotechnology; Bolus Infusion; Cancer Patient; Canis familiaris; Cessation of life; Charge; Chemistry; Chitosan; Chronic Disease; Cisplatin; Clinic; Collaborations; Data; Development; Diffusion; Distant; Dose; Drug Controls; Drug Delivery Systems; Drug Formulations; Early Diagnosis; Encapsulated; Entrepreneurship; FDA approved; Figs - dietary; Foundations; Funding; Future; Goals; Hamsters; Hand; Health Care Costs; Home environment; Hour; In Vitro; Injection of therapeutic agent; Institutes; Intravenous; Investigation; Kidney; Kinetics; Lesion; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of pharynx; Masks; Membrane; Modeling; Monitor; Morbidity - disease rate; Mus; Nanotechnology; Neoplasm Metastasis; Oral; Organ; Paper; Particle Size; Patients; Persons; Pharmaceutical Preparations; Phase; Plasticizers; Platinum; Polymers; Premalignant; Privacy; Property; Provider; Research; Safety; Severities; Staging; Surface; Survival Rate; System; Taste Buds; Taste Perception; Techniques; Technology; Therapeutic; Tissue Model; Tissues; Toxic effect; Travel; Treatment Efficacy; base; cancer site; cancer surgery; cancer therapy; chemotherapy; compliance behavior; controlled release; cost; design; drug efficacy; efficacy evaluation; experience; improved; in vivo; innovation; killings; malignant mouth neoplasm; mortality; nano; nanodrug; nanoencapsulated; nanoengineering; nanoparticle; novel; oncology; preclinical study; prevent; public health relevance; skills; success; tumor

DESCRIPTION (provided by applicant): According to the Oral Cancer (OC) Foundation, oral and pharyngeal cancer will cause 8,000 deaths this year, killing roughly one person per hour. Currently, cisplatin (CIS) is at the forefront of platinum- based chemotherapeutics for treating OC. However, its efficacy is often hindered by its significant systemic toxicity as a result of traditional bolus systemic intravenous (IV) doses. In this proposal, Privo's specific aims focus on developing and optimizing an effective and safe nano engineered drug delivery platform, i.e., chemo-wafer (CW) that reformulates a known anticancer chemotherapy agent ( e.g. cisplatin) for the local and topical treatment of OC, thus replacing injection, increasing the drug's efficacy and significantly reducing its systemic toxicity. The CW platform contains FDA approved chemotherapy drugs and generally recognized as safe (GRAS) materials. It utilizes nano-encapsulation techniques to incorporate drugs into NPs with a controlled-release design that releases chemo drugs at fully tunable and pre-determined rates. The design has the potential to deliver a highly concentrated amount of chemotherapy agents directly to the cancer tissue while minimizing toxic side effects to the surrounding healthy tissues. Part of the project is the development of a novel bilayered vehicle, CW, consisting of a NP front end and a plasticized, non-porous, non-permeable back end. It consists of a mucoadhesive material with unidirection delivery of the drug, which prevents the chemo agent from reaching the taste buds. This addresses the unpleasant taste issues, and increases patient compliance. This project can change the chemotherapy treatment of OC patients by replacing IV delivery with topical delivery of CW, significantly reducing the overall cost of OC treatment. The American Cancer Society has emphasized that oral chemotherapy is truly the wave of the future for oral cancer treatments because it offers patients distinct advantages over traditional IV. The 5- year survival of patient with OC has not significantly improved over the past several decades. Moreover, the survival rate for early detection is significantly higher than later stages (80-90% vs. 25- 35%). Therefore, for patients with pre-malignant to non-metastasized malignant OC, this reformulated nano-encapsulated CW delivery platform has the opportunity to considerably reduce the morbidity and mortality rate of this devastating cancer. The CW has the potential to be administered by the patient and in the privacy of their own homes, avoiding the inconvenience of travel to and from chemotherapy clinics and reducing healthcare cost. The ultimate objectives of Privo Technologies are to develop and commercialize an effective, safe and convenient chemotherapy treatment accessible to many OC patients.

根据口腔癌（OC）基金会的数据，口腔癌和咽癌今年将导致8,000人死亡，大约每小时一人死亡。目前，顺铂（CIS）是治疗OC的铂基化疗药物的最前沿。然而，由于传统的推注全身静脉内（IV）给药，其疗效往往受到其显著全身毒性的阻碍。在这份提案中，Privo的具体目标集中在 开发和优化了一种有效、安全的纳米工程药物传递平台，化学晶片（CW），重新配制已知的抗癌化疗剂（例如顺铂），用于OC的局部和局部治疗，从而取代注射，提高药物的疗效 并显著降低其全身毒性。CW平台包含FDA批准的化疗药物和公认安全（GRAS）材料。它利用纳米封装技术将药物掺入具有控释设计的NP中，该设计以完全可调和预定的速率释放化疗药物。该设计有可能将高浓度的化疗药物直接输送到癌组织，同时最大限度地减少对周围健康组织的毒副作用。该项目的一部分是开发一种新型的双层车辆，CW，包括一个NP前端和一个塑化，无孔，非渗透性后端。它由具有药物单向递送的粘膜粘附材料组成，其防止化疗剂到达味蕾。这解决了令人不快的味道问题，并增加了患者的依从性。该项目可以改变OC患者的化疗治疗，用CW的局部递送代替IV递送，显著降低OC治疗的总体费用。美国癌症协会强调，口服化疗确实是口腔癌治疗的未来潮流，因为它为患者提供了比传统IV明显的优势。在过去的几十年里，OC患者的5年生存率没有显著提高。此外，早期发现的存活率明显高于晚期（80-90% vs. 25- 35%）。因此，我们认为， 对于患有癌前病变至非转移性恶性OC的患者，这种重新配制的纳米封装CW递送平台有机会显著降低这种毁灭性癌症的发病率和死亡率。CW有可能由患者在自己家中进行管理，避免往返化疗诊所的不便，并降低医疗保健成本。Privo Technologies的最终目标是开发和商业化一种有效，安全和方便的化疗治疗方法，使许多OC患者都能获得。